1-(Bromomethyl)-4-(trifluoromethyl)benzene → 4,4-Dimethyl-2-(adamantan-2-yl)-1-[4-(trifluoromethyl)benzyl]-1,2-diazetidin-3-one
Reaction equation
[CH:1]12[CH2:10][CH:5]3[CH2:6][CH:7]([CH2:9][CH:3]([CH2:4]3)[CH:2]1[N:11]1[C:14](=[O:15])[C:13]([CH3:17])([CH3:16])[NH:12]1)[CH2:8]2.[F:18][C:19]([F:29])([F:28])[C:20]1[CH:27]=[CH:26][C:23]([CH2:24]Br)=[CH:22][CH:21]=1>>[CH3:16][C:13]1([CH3:17])[N:12]([CH2:24][C:23]2[CH:22]=[CH:21][C:20]([C:19]([F:18])([F:28])[F:29])=[CH:27][CH:26]=2)[N:11]([CH:2]2[CH:3]3[CH2:4][CH:5]4[CH2:6][CH:7]([CH2:8][CH:1]2[CH2:10]4)[CH2:9]3)[C:14]1=[O:15]Participants
3
Procedure
2-(Adamantan-2-yl)-4,4-dimethyl-1,2-diazetidin-3-one and 4-(trifluoromethyl)benzyl bromide were used for a similar reaction and treatment as Process 6 of Example 1, and the title compound was obtained as a white crystalline powder.
Sources & evidence
- ORD record
- ord-df4c82d4ca8e4478b2174f3caed6ffae
- Source dataset
- uspto-grants-2012_08
- Patent number
- US08252781B2
Reaction notes
Loading…